NasdaqGS:BNTXBiotechs
Did New Gotistobart Data Just Shift BioNTech's (BNTX) Oncology-Led Diversification Narrative?
In early December 2025, BioNTech and its partners OncoC4 and Bristol Myers Squibb reported past trial data showing that their experimental cancer therapies gotistobart and pumitamig improved outcomes versus standard care in difficult-to-treat lung and triple-negative breast cancers, with manageable safety profiles and ongoing Phase 3 programs.
These oncology readouts suggest BioNTech’s pipeline is starting to yield clinically meaningful assets in high-need solid tumors, potentially...